Utah is testing the boundaries of AI in medicine with a pilot that lets residents renew prescriptions through a chatbot from startup Doctronic—no office visit required. The program, approved under the state’s “regulatory sandbox,” has ignited a clash over who gets to practice medicine and how AI should be policed. A state-appointed board of AI specialists—not physicians—oversees the pilot; during the initial phase, doctors review all renewals, though Doctronic plans to fully automate refills. Physicians and medical boards, blindsided by the January launch, warn of safety risks from renewing complex drugs, such as blood thinners, without fresh clinical review. The FDA hasn’t authorized AI chatbots and signals a light-touch approach, leaving a regulatory gray zone between state licensure and federal device oversight. Backers, including policy groups promoting formal AI licensure, say automation will expand access and ease workloads; critics say the evidence is thin—Doctronic cites an unpublished study showing 80% diagnostic concordance—and fear public backlash if errors mount. With Texas and Wyoming easing rules and other states weighing AI licensure, companies may scale ahead of standards, testing patient trust and the limits of medical regulation.
Related articles:
– NIST AI Risk Management Framework
– Ethics and governance of artificial intelligence for health (WHO)
